We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals
News

ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals

ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals
News

ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProBioGen AG has announced signing a contract with Virdante Biopharmaceuticals, Inc., a US-based biopharmaceutical development company.

ProBioGen will contribute producer cell line development and process engineering for one of Virdante’s proprietary therapeutic proteins. Virdante’s protein products are unique in that they incorporate the company’s proprietary “Sialic Switch” technology that improves the anti-inflammatory properties of an antibody for autoimmune and inflammatory diseases. Virdante selected ProBioGen for its expertise in developing royalty-free pharmaceutical cell lines and robust, economical processes for GMP-manufacturing.

“We are highly impressed by Virdante´s products and strategies and their compelling scientific rationale to improve human proteins. We are excited to contribute our knowledge in harnessing the cellular machinery to maximize productivity for this ambitious project“, commented Dr. Volker Sandig, Chief Scientific Officer of ProBioGen.
Advertisement